{
    "id": "wrong_mix_property_foundationPlace_00119_2",
    "rank": 60,
    "data": {
        "url": "https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1",
        "read_more_link": "",
        "language": "en",
        "title": "Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine",
        "top_image": "https://www.medrxiv.org/sites/default/files/images/medrxiv_logo_homepage7-5-small-test-up.png",
        "meta_img": "https://www.medrxiv.org/sites/default/files/images/medrxiv_logo_homepage7-5-small-test-up.png",
        "images": [
            "https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png",
            "https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif",
            "https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/reddit.png",
            "https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png",
            "https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png",
            "https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png",
            "https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "David Cooper",
            "Robert W. Frenck",
            "Laura L. Hammitt",
            "Özlem Türeci",
            "Haylene Nell",
            "Axel Schaefer",
            "Serhat Ünal",
            "Qi Yang",
            "Paul Liberator",
            "Dina B. Tresnan"
        ],
        "publish_date": "2021-07-28T00:00:00",
        "summary": "",
        "meta_description": "medRxiv - The Preprint Server for Health Sciences",
        "meta_lang": "en",
        "meta_favicon": "https://www.medrxiv.org/sites/default/files/images/favicon.ico",
        "meta_site_name": "medRxiv",
        "canonical_link": "https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1",
        "text": "Competing Interest Statement\n\nAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf\n\nClinical Trial\n\nNCT04368728\n\nFunding Statement\n\nSupported by BioNTech and Pfizer.\n\nAuthor Declarations\n\nI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.\n\nYes\n\nThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:\n\nThe trial was conducted in accordance with the protocol, the ethical principles derived from international guidelines including the International Council for Harmonisation Good Clinical Practice Guidelines, the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, and applicable laws and regulations (including applicable privacy laws). An independent data monitoring committee reviewed efficacy and unblinded safety data. Institutional Review Board or Ethics Committee approval was obtained for each site prior to enrollment of any study participant. The list of Institutional Review Board Committees is summarized at the end of the Supplementary Appendix.\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes"
    }
}